Background: Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) pandemic has led to over 44 million cases and 724,000 deaths in the US. It is the third leading cause of morbidity and mortality. We present an uncommon case of COVID-19 induced myopericarditis with cardiogenic shock. Case: A 68-yr-old male presented with progressive dyspnea, chest pain and fatigue and fever for 8 days. On day of admission (DOA) 1, he was hypotensive, tachypneic and desatd. Labs included pos. COVID PCR, cardiac troponin I (cTnI) 361ng/mL, BNP 4,360pg/mL, CRP 20mg/dL, and interleukin 6 (IL-6) level 231pg/mL. Electrocardiog. revealed incomplete right bundle branch block and LVH. Echocardiog. showed severe global LV hypokinesis and ejection fraction of 25%. Coronary angiog. revealed non-obstructive CAD with TIMI-3 flow with elevated LV end-diastolic filling pressures. Respiratory viral panel and antinuclear antibody were neg. No clin. improvement with dexamethasone use by DOA 3. Decision-making: IV methylprednisolone 500mg was administered for three days. Vasopressors were slowly weaned off. He was discharged by DOA 7 on nasal cannula oxygen and steroid taper. Conclusion: COVID-19 induced, cytokine storm-mediated myocardial cellular damage, myopericarditis and cardiogenic shock are rare but emerging complications of COVID-19 infection. Our case highlights the role of prompt use of higher dose of corticosteroids and the utility of IL-6 level as a cardinal prognostic marker.